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Abstract: Osteonecrosis of the jaw (ONJ) is a severe clinical condition characterized mostly but not
exclusively by an area of exposed bone in the mandible and/or maxilla that typically does not heal
over a period of 6–8 weeks. The diagnosis is first of all clinical, but an imaging feedback such as
Magnetic Resonance is essential to confirm clinical suspicions. In the last few decades, medication-
related osteonecrosis of the jaw (MRONJ) has been widely discussed. From the first case reported
in 2003, many case series and reviews have appeared in the scientific literature. Almost all papers
concerning this topic conclude that bisphosphonates (BPs) can induce this severe clinical condition,
particularly in cancer patients. Nevertheless, the exact mechanism by which amino-BPs would be
responsible for ONJ is still debatable. Recent findings suggest a possible alternative explanation for
BPs role in this pattern. In the present work we discuss how a condition of osteomalacia and low
vitamin D levels might be determinant factors.
Keywords: aminobisphosphonates; BRONJ; denosumab; MRONJ; osteomalacia; osteonecrosis;
jaw; pathophysiology
1. Introduction
Osteonecrosis of the jaw (ONJ) is a severe clinical condition characterized by an
area of exposed bone in the mandible and/or maxilla that typically does not heal over
a period of 6–8 weeks. The diagnostic criteria were updated in 2014 by the American
Association of Oral and Maxillofacial Surgeons and based on clinical features and radiologic
imaging in presence of pharmacological history or ongoing use of antiresorptive agents, in
particular bisphosphonates (BPs) or antiangiogenic agents such as monoclonal antibodies
targeting vascular endothelial growth factor (VEGF) receptors [1]. A special committee
of the American Association of Oral and Maxillofacial Surgeons (AAOMS) suggested
changing the nomenclature of bisphosphonate-related osteonecrosis of the jaw (BRONJ)
to medication-related osteonecrosis of the jaw (MRONJ) as a consequence of increasing
cases of osteonecrosis due to the association with other antiresorptive and antiangiogenic
therapies [1]. However, the nomenclature concerning this pathology has been and still is
the subject of debate [2–5]. MRONJ classification considers four disease stages. Stage 0—the
prodromal period. No clinical evidence of necrotic bone, and nonspecific clinical findings,
radiographic changes, and symptoms. Radiographically, it can reveal an unexplained bone
loss not attributed to periodontal inflammation with a change in trabecular bone pattern;
Stage 1—Exposed and necrotic bone, or fistulae that probe to the bone in asymptomatic
patients who have no evidence of infection. These patients may also present with the
radiographic findings mentioned for Stage 0 which are localized to the alveolar bone
region; Stage 2—Exposed and necrotic bone, or fistulae that probe to the bone, associated
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with infection as evidenced by pain and erythema in the region of the exposed bone, with
or without purulent drainage. These patients are typically symptomatic; Stage 3—Exposed
and necrotic bone, or fistulae that probe to bone, with evidence of infection, and one or more
of the following: (1) exposed necrotic bone extending beyond the region of alveolar bone,
i.e., inferior border and ramus in the mandible, maxillary sinus and zygoma in the maxilla;
(2) pathologic fracture; (3) extraoral fistula; (4) oral antral/oral nasal communication;
(5) osteolysis extending to the inferior border of the mandible or sinus floor [1].
The diagnosis is first of all clinical, but 3D imaging techniques (CT, cone beam), Single-
Photon Emission Tomography (SPECT) and Magnetic Resonance (MR), are important to
confirm the clinical suspicions. In the last decade, the problem of ONJ has been widely
discussed. From the first case reported in 2003, many additional case series and reviews
appeared in the scientific literature. Almost all publications concerning this topic conclude
that BPs, antiresorptive and antiangiogenic drugs can induce this severe clinical condition,
particularly in cancer patients. Generally, antiresorptive drugs are bone targeting agents
used to prevent skeletal resorption following different pathologies such as metabolic and
degenerative diseases. In addition to bone targeting drugs, medications without antiresorp-
tive properties such as angiogenic inhibitors, tyrosine kinase inhibitors or inhibitors of the
mammalian target of rapamycin (mTOR) and cytotoxic molecules used for chemotherapy
may also increase the risk of osteonecrosis of the jaw [6].
Nevertheless, the exact mechanism by which these drugs, in particular amino-BPs,
would be responsible for MRONJ is still subject to discussion. However, many hypotheses
have been proposed and different pathophysiological mechanisms have been investigated,
supporting the main role of drugs in the pathogenesis of this severe condition.
Among other hypotheses, osteomalacia following vitamin D deficiency has been
considered an important factor in the pathogenesis of ONJ.
Therefore, with the aim to describe the ONJ problem and the medical context of this
pathology, in this review we discuss recent studies related to ONJ and antiresorptive drugs,
as well as the involvement of osteomalacia due to low vitamin D levels as a triggering
factor for ONJ.
2. Epidemiology
ONJ lesions occur more commonly in the mandible than in the maxilla (65% mandible,
28.4% maxilla, 6.5% both mandible and maxilla, 0.1% other locations). ONJ incidence in
patients who are prescribed oral BPs for the treatment of osteoporosis is very low and
ranges from 1.04 to 69 per 100,000 patient-years. The incidence of ONJ in patients prescribed
intravenous (i.v.) BPs for the treatment of ONJ ranges from 0 to 90 per 100,000 patient-years.
With regard to denosumab, ONJ incidence ranges from 0 to 30.2 per 100,000 patient-years [7].
Based on different national surveys the incidence of ONJ in osteoporotic patients receiving
BPs ranged from 0.01% to 0.07% [8,9]. On the basis of these epidemiologic data, ONJ impact
on the osteoporotic population appears to be very rare and therefore negligible.
In cancer patients treated with i.v. BPs the incidence of ONJ is higher, ranging from
0 to 12,222 per 100,000 patient-years [7]; recently, an incidence of about 0.8% (48 out of
6018) in breast cancer patients has been observed [10]. However, ONJ incidence in this
particular setting may be influenced by the malignancy type/severity as well as by the
assumption of other drugs that may impact bone health, such as glucocorticoids. In
addition, in the presence of bone metastases, the doses of drugs used for the management
of bone disease are significantly higher compared to those used in osteoporosis, therefore
the oncologic setting appears to be very peculiar compared to other clinical conditions
involving the skeleton.
Considering the epidemiological data discussed so far and the prognostic clinical
impact of fragility fractures increasing morbidity and disability, as well as mortality, the
precautionary interruption of an antifracture treatment should be carefully evaluated. If
we assume that an antiresorptive therapy may grant a long-term fracture risk reduction of
around 30%, the benefit/risk ratio (prevented fracture/adverse skeletal event), particularly
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in high-risk subjects, would be at least 100:1 [11]. In addition, as has been recently ob-
served, the interruption of the antiresorptive therapy, in particular denosumab treatment,
is associated with a significant fracture rate increase [12].
However, it is important to highlight that, even in long-term treatments, serious
adverse event rates are generally stable over time, varying between 11.5 and 14.4 per
100 participant-years, against a 10.9 to 11.7 withdrawal per 100 participant-years in
placebo [11,13]. These data further support the pursuance of antifracture therapy in high-
risk patients. From another point of view, emerging evidence confirms that antiresorptive
drug treatment discontinuation aimed at ONJ risk reduction is unneeded [14].
3. Clinical and Genetic Risk Factors for ONJ
Many clinical factors have been considered in the pathogenesis of ONJ, particularly
dental surgery. A recent study reported that in 48 patients ONJ triggers were: dental extrac-
tion in 20 of them (35.1%), periodontal disease in 14 (24.6%), denture trauma in 6 (10.5%),
other dental surgery in 2 (3.5%). Spontaneous ONJ was observed in 20 patients (35.1%).
Infection was present in 13/27 (48.1%) induced ONJ and in 7/18 (38.9%) spontaneous
ONJ cases [10].
The patients’ features are also important: immunodeficiency, comorbidities such as
diabetes as well as the presence of autoimmune diseases have been suggested as risk
factors for ONJ [15]. The local triggering factors were examined in a recent review: tooth
extraction was reckoned in 46% of individuals, implant placement in 14%, prosthetic
trauma in 14% [16].
Genetic and epigenetic studies have been performed to evaluate individual risks of
developing ONJ in patients treated with antiresorptive drugs. It has been reported that
the A allele frequency of the A/C rs2297480 polymorphism of farnesyl pyrophosphate
synthase (FDPS), an enzymatic target of BPs, correlates positively with ONJ after 18–24
months of zoledronate treatment [17]. A genome-wide association study (GWAS), has
reported that a single nucleotide polymorphism (SNP) occurring in Cytochrome p450
CYP2C8 is associated with a higher risk to develop ONJ in patients affected by multiple
myeloma treated with BP therapy [18]. An exome-wide association analysis (ExWAS),
highlighted two SNPs on chromosome 10 occurring in two promoter sequences of the
SIRT1/HERC4 locus which seemed to be associated with MRONJ [19]. On the other hand,
the promoter SNP rs932658 regulates the expression of SIRT1 and presumably lowers the
risk of MRONJ by increasing SIRT1 expression [20]. According to this hypothesis, in the
presence of high concentrations of BP in bone, or with frequent intravenous dosing, toxicity
to other bone cells including soft tissue might occur. Concerning this aspect, the potential
role of cumulative doses of BPs in fostering the onset of bone alterations seems unlikely,
particularly for zoledronic acid [8]. In fact, ONJ has been observed with a wide range of BP
doses, varying from a single dose of zoledronic acid (4 mg) to 60 administrations [8]; risk
increases dramatically with higher cumulative doses, higher administrations, and longer
observation time.
In such a complex scenario the precise role and action course of BPs, denosumab
or antiangiogenic drugs in MRONJ is still under discussion. It is important to ascertain
whether they are the main culprits or rather detrimental factors, among others, in the
pathogenesis of ONJ. Such elucidation would improve the management of patients at high
fracture risk requiring long-term antifracture treatments.
4. Bone Remodeling Impairment
Bone remodeling is a crucial lifelong process that allows old bone tissue removal
from the skeleton and its replacement with new bone. It also ensures bone reshap-
ing/replacement following fractures and microdamage. Osteoclasts (OC) literally “bone-
breaking cells”, perform bone resorption, while osteoblasts (OB) produce the collagen
rich extracellular matrix and participate in its mineralization. Osteoclast and osteoblast
activity must be balanced through coupling in order to maintain skeletal mass throughout
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the lifespan; however, certain diseases and aging itself lead to unbalanced pathological
conditions. Regarding the topic under discussion in the present review, impairment of
osteoclast-mediated bone remodeling and angiogenesis have been reckoned to play a major
pathogenetic role in MRONJ [21,22]. The site-specific effect, restricted to the jaw bone, is
ascribed to a differentiated proliferation and osseous response to BPs by craniofacial bones,
due to their different embryonic origin (i.e., from the cranial neural crest). Antiresorptive
drugs (BPs and Denosumab) target OCs but affect OBs as well. Bone homeostasis depends
on OC/OB crosstalk which is regulated by the RANK-RANKL-OPG network; osteoclasts
targeting drugs might favor ONJ by disrupting the coupling process [23]. Osteocytes,
mature osteoblasts embedded into the mineralized matrix, which are the most abundant
and long-lived cells in bone, play an important role in bone remodeling control, by secret-
ing Sclerostin and DKK1, two inhibitors of WNT signaling pathway, and RANKL, which
reduce bone formation (Figure 1). In vitro experiments on MLO-Y4, an osteocyte-like cell
line, have shown that Zoledronate administration significantly enhanced both RANKL and
Sclerostin expression [24]. These data demonstrate that BPs also exert their influence on os-
teocytes, suggesting osteocytes’ potential role in MRONJ development. Jaw predisposition
to MRONJ is justified by the very rapid turnover rate in alveolar bone [25].
Figure 1. Schematic representation of Osteoclast/Osteoblast/Osteocyte cross-talk mediators involved
in bone remodeling. OC: osteoclast; OB: osteoblast; OT: osteocyte; blc: bone lining cell. DKK1:
Dickkopf WNT signaling pathway inhibitor 1; RANKL: Receptor activator of nuclear factor kappa-
B ligand; RANK: Receptor activator of nuclear factor kappa-B; OPG: osteoprotegerin, a RANKL
decoy receptor.
5. How Do Different Antiresorptive Drugs Interfere with Bone Turnover
In respect to turnover suppression, we have previously observed that zoledronic acid
increases the anabolic window preserving bone formation activity compared to other less
powerful BPs such as risedronate, avoiding the so-called frozen bone [26,27]. From another
point of view, Reid in 2009 suggested that MRONJ is caused by powerful BPs direct toxicity
to bone and soft tissue cells, probably deriving from their effects on the mevalonate path-
way [28]. BPs concentration in the jaw can be higher compared to other skeleton areas [29].
In fact, BPs preferably affect this area in consequence of its higher remodeling and turnover
rate. By suppressing bone metabolism, BPs may induce physiological microdamage in the
jaw affecting its biomechanical abilities. In addition, a lower pH consequent to oral invasive
procedures allows BPs accumulation, i.e., toxic concentrations. It has been suggested that
the fostering factors for MRONJ are: BPs potency, treatment duration, concomitant oral
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surgery [30,31]. In addition to BPs, other therapeutic molecules can inhibit osteoclasts like
denosumab, an anti-RANKL monoclonal antibody is currently used for the treatment of
osteoporosis, primary and metastatic bone cancer as well as rheumatoid arthritis [32–34].
However, cases of ONJ have been reported in patients receiving denosumab [35,36].
6. Animal Models Contribution to ONJ Studies
A suitable animal model is necessary to better understand the pathophysiology of
ONJ. The challenging task is to generate animal models showing signs similar to ONJ
clinical picture [37]. The in vivo model should expose the oral cavity bone following
bisphosphonate treatment in association with other factors occurring in humans such as
dental trauma or immunosuppression [38,39]. It is important to consider that ONJ occurs
in humans after at least 8 weeks exposure. Timing may vary for animal models. Therefore,
establishing the correct timeline for the observation of ONJ effects represents a starting
point for studies related to the physiology and pathophysiology of the jaw.
Studies performed in dogs demonstrated that the bone turnover rate in the jaw is
6/10-fold higher than in long bones. Such bone turnover might increase 10-fold further
upon dental extraction [40,41].
Since BPs affect bone by suppressing its turnover, the suppression/reduction of bone
turnover might be considered the main cause of ONJ pathophysiology [42,43]. As intra-
cortical remodeling suppression is a favoring factor for ONJ, it has been hypothesized
that animal species with intracortical remodeling may render ONJ effects more appropri-
ately [37]. Allen et al. have chosen dogs, characterized by intracortical remodeling in the
skeleton and, in particular, in the jaw. For this purpose, the authors used intact female
beagles treated daily with vehicle or alendronate (0.20 or 1.0 mg/kg/day) and the duration
of this treatment was one or three years. During this study the authors reported exposed
oral bone absence in all animals; jaw matrix necrosis areas were observed in 25% of dogs
treated with the lower doses, in 17% or 33% of dogs treated with the higher dose after
1 year or 3 years, respectively [37].
Another suitable animal model for studying ONJ is the rodent. Rodents are widely
used for studies related to skeletal diseases. However, the absence in rodents of intracortical
remodeling, a favoring factor for ONJ, generally limits their use. However, it has been
demonstrated that intracortical turnover occurs in C3H mice long bones [44] suggesting
that selected mice strains may be useful for studying ONJ.
Recently, Holtmann et al. consulted Embase, Medline, and the Cochrane Library in
order to identify the appropriate model for MRONJ [45]. In this retrospective study, the
authors found that rats, mice, dogs, minipigs, sheep and rabbits were the most used animal
models. In particular, studies performed on the rat model focused on BPs’ effects on the
jaw after tooth extraction. According to Vasconcelos et al. clodronate (a nonamino-BPs),
was less likely to induce ONJ than zoledronate [46]. However, most of the other studies em-
ployed amino-BPs such as zoledronate, alendronate or pamidronate. Studies performed by
using zoledronate in rats clearly showed the effects of ONJ [47], while the administration of
alendronate showed controversial results. The combined use of an amino-bisphosphonate
plus a corticosteroid led to the appearance of ONJ-like lesions [48]; Sonis et al. observed
in rats treated with bisphosphonate and corticosteroid more relevant ONJ lesions than
in zoledronate-only administration [49]. Aghaloo et al. observed that periodontitis is a
triggering factor for the development of ONJ with high-dose administration of zoledronate;
other studies confirm these results [50].
In studies employing murine models the effects of bisphosphonate in association with
corticosteroids compared to the effects of zoledronate alone have also been investigated.
The combination of bisphosphonate together with corticosteroids seems to enhance the
development of ONJ lesions following tooth extraction in mice. However, other authors
did not observe these effects [51]. In addition, it has been demonstrated that the presence
of a periapical disease in mice promotes ONJ following zoledronate administration or
treatment with the anti-receptor activator of nuclear factor kappa beta ligand antibody
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(anti-RANKL Ab) [52]. Such a finding has not been observed in rats. In studies using a
pig model or a sheep model treated with zoledronate alone or zoledronate in association
with corticosteroids, respectively, the presence of ONJ lesions was observed [53–55]. Pig
is a very useful model for studying skeletal diseases as its bone regeneration pattern is
similar to what is expected in humans [53]. In particular, the minipig is considered the
most reliable model for ONJ pathophysiology investigations [53,54]. Yet, due to actual
bone physiology differences, the direct translation of animal model findings to human ONJ
pathophysiology is questionable.
7. Osteomalacia and Vitamin D
Osteomalacia is characterized by low phosphate levels causing impaired bone miner-
alization, bone pains, myopathies and enthesopathies. In addition to hypophosphatemia,
biochemical aspects include normal or low levels of serum calcium, normal or high levels
or alkaline phosphatase, low or insufficient levels of serum 1, 25 dihydroxy vitamin D
as well as normal serum intact parathormone levels and alterations related to the maxi-
mum tubular resorptive capacity for phosphorus/glomerular filtration rate [56,57]. The
causes of osteomalacia may be identified in underlying mechanisms such as vitamin D de-
ficiency/resistance, vitamin D-independent low calcium serum levels, hypophosphatemic
diseases, mineralization impairment due to aluminum toxicity (antacids, dialysis fluid),
fluorosis (i.e., endemic fluorosis from borehole water) iron (in dialysis patients, or patients
with FGF23 mediated hypophosphatemia), etidronate overdose (in Paget’s disease), or
environmental intoxication with cadmium [58]. In addition, metabolic acidosis occurring
in gastrointestinal or renal disorders may contribute to bone mineralization disruption [58].
Recently, the involvement of FGF23, an osteocyte-borne hormone, in osteomalacia has been
suggested [59]. Osteomalacia can also be related to congenital connective tissue disorders
such as osteogenesis imperfecta type VI [60] or the rare fibrogenesis imperfecta ossium [61].
However, the actual prevalence of osteomalacia is elusive. In the Middle East and Asia
low calcium intake and severe vitamin D deficiency are common; in Pakistan a preva-
lence of 2% to 3.6% of diagnosed osteomalacia has been reported in young women [62].
In Western countries elderly people are at high risk of osteomalacia: a 2% to 5% preva-
lence for this disorder has been reported in different studies [63,64]. Interestingly, a larger
number of biopsies revealed a 4.9% prevalence of individuals with osteomalacic features
in Germany [65]. In addition, osteomalacia is present in patients with gastrointestinal
disorders (i.e., celiac disease) [66]. After gastric bypass surgery, patients may develop
vitamin D deficiency even if only 25% of these bariatric patients with suspected osteoma-
lacia will be actually confirmed as osteomalacic by histomorphometric analyses [67,68].
Hypovitaminosis D has been found in prostate, multiple myeloma, colorectal and breast
cancer patients [69]. In particular, Nogues et al. found vitamin D deficiency in 85–92%
of breast cancer patients [70] whereas Neuhouser et al. reported a prevalence of 76.8% of
vitamin D insufficiency in a study conducted on 426 breast cancer survivors [71]. Other
studies conducted on breast cancer patients confirmed a prevalence >70% of vitamin D
deficiency [72–74]. Fakih et al. reported in a study performed on colorectal cancer patients
that 21% stage I-III patients and 32% stage IV patients had very low vitamin D serum levels
(<15 ng/mL) [75]. Trump et al., performing a case control study in prostate cancer patients
reported vitamin D deficiency (<20 ng/mL) and insufficiency (20–31 ng/mL) in 40% and
32% of cases respectively; notably, the authors found 31% vitamin D deficiency and 40%
insufficiency among controls [76]. Finally, an alarming study reported vitamin D deficiency
in metastatic bone disease and multiple myeloma patients [77]. In this study the authors
reported that serum 25-OH-D levels are rarely sufficient in breast, prostate or MM bone
metastatic patients.
8. Vitamin D and Oral Pathology
Various studies highlight the role of vitamin D in oral pathology. Vitamin D plays
an important role in periodontology as it contributes to maintaining healthy periodontal
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tissues, reducing the risks of gingivitis and chronic periodontitis by activating the immune
response [78]. A study performed in 562 senior citizens demonstrated that subjects receiv-
ing a high vitamin D dose (>800 IU daily) showed a lower risk of developing a severe
form of chronic periodontitis compared to those receiving a lower vitamin D daily dose
(<400 IU) [79]. Furthermore, the association between low levels of vitamin D intake and
increased caries risk has been reported in children in different studies [80–83]. The alleged
association between vitamin D deficiency and ONJ is an intriguing topic. In fact, some re-
searchers did not find such an association [84], while others have observed that low vitamin
D levels are risk factors for the development of ONJ [85,86]. In particular, in a randomized
study performed in osteoporotic patients no correlation between vitamin D intake and ONJ
was found [84]. On the contrary, MRONJ prevalence was reported in patients with low
vitamin D levels in a two-year retrospective study performed in 63 patients treated with
antiresorptive medication [85]. Recently, Demircan et al. performed a case control study
(20 patients with ONJ and 20 healthy controls) in order to evaluate bone marker levels in
bisphosphonate-induced-ONJ [86]. Interestingly, the researchers found higher PTH levels
and lower TSH, Vit-D, osteocalcin and NTX levels in ONJ patients compared to controls.
9. Histomorphometric Study
Some years ago, the results of a histomorphometric study performed in our laboratory
suggested a possible novel explanation for BPs’ role in this pattern [87]. In the cited
study, we performed jaw bone biopsies in patients treated with BPs with or without ONJ
and we found a mineralization defect in the jaws of all ONJ patients, highlighting the
presence of osteomalacia at the histological level (Figure 2). On the contrary, control
subjects did not show any osteomalacic pattern in jaw biopsies. Furthermore, control
subjects, who had been followed up as part of a cohort study, did not develop any sign
of MRONJ up to one year after bone sampling. Interestingly, four patients who had been
excluded from the study because of osteomyelitis, turned out to be osteomalacic upon
histomorphometric evaluation of jaw biopsies and developed clinical and/or radiological
signs of MRONJ within six months, suggesting the mineralization defect to be a pivotal
factor in the pathogenesis of ONJ.
From the histological point of view, osteomalacia is characterized by inadequate or
delayed mineralization of osteoid in mature cortical and spongy bone, leading to bone
softening and sclerosis. When these aspects are referred to the jaw, they appear consistent
with the ONJ stage 0 characteristics. Furthermore, the osteomalacic condition might be a
necessary but not sufficient prodromal condition for ONJ development. This histologic pat-
tern may facilitate inflammatory/infective processes preventing complete bone restoration,
which may be further biased by BP administration. Whether osteomalacia in ONJ patients
is a local phenomenon or a systemic condition is still questionable. However, this is not
a relevant issue, since even focal osteomalacia can lead to the previously described bone
alterations characterizing ONJ.
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Figure 2. Histological section of the jaw. Left panels show biopsy from patient with Osteonecrosis of the jaw (ONJ),
Goldner-stained (A) and tetracycline double labeling sections (B). Right panels represent an age-matched control subject.
Note the large quantity of unmineralized osteoid ((A), red color, white arrows), area of woven bone ((A), black arrow),
lacking the double labeling ((B), yellow arrows) in ONJ compared to control (C,D). These findings represent the histological
pattern of a mineralization defect (magnification 200×).
10. Discussion and Conclusions
On the basis of the histomorphometric results discussed above, BPs’ role in the patho-
genesis of ONJ should be reviewed. In particular, as has been described previously for
patients with bone diseases, the treatment with BPs in the presence of osteomalacia can
emphasize a mineralization defect [88]. Consequently, BPs’ contribution to the pathogene-
sis of ONJ might be secondary to the osteomalacic condition. The finding of an impaired
turnover, consequent to the mineralization defect, rather than an excessive osteoclasts
inhibition induced by BPs or by other antiresorptive agents, represents a new insight in
the pathogenesis of ONJ. Moreover, it is worth stressing that more powerful antiresorptive
agents (e.g., zoledronic acid and denosumab) contribute more to MRONJ pathogenesis
than less powerful and structurally different molecules such as clodronate or oral for-
mulations [89,90]. Recently, it has been observed that nonamino-BPs could also prevent
ONJ due to their most potent antioxidant and anti-inflammatory activities [91]. On the
other hand, an osteomalacic pattern, frequently secondary to vitamin D deficiency, rather
than BPs potency or cumulative doses, may explain the high incidence of ONJ in cancer
patients (Figure 3).
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Figure 3. Graphical updated pathophysiologic mechanism of medication-related osteonecrosis of the jaw (MRONJ): In
immunosuppressed patients (causes: cancer, chemotherapy, corticoids), surgical interventions and/or poor oral hygiene
promote an osteomyelitis complication. In the presence of osteomalacic bone, the use of aminobisphosphonates (ABPs)
contributes, through several pathways, to hamper bone healing and to promote the osteonecrosis process.
In fact, cancer patients and immunocompromised patients in general, show a high
prevalence of hypovitaminosis D, which is very difficult to correct; they actually need
higher doses of cholecalciferol than healthy subjects [72]. In these patients the hormone
deprivation or, in general hypogonadism, may promote hypovitaminosis D [92]. Notably,
not all patients with an osteomalacic histological pattern show hypovitaminosis D: this sug-
gests the presence of focal osteomalacia in some of them. This situation has been described
already in kidney transplant patients characterized by immunocompromised status, low
bone turnover and osteomalacic pattern, suggesting vitamin D resistance [93]. In such
cases, higher doses or alternatively vitamin D active metabolites should be administered in
order to overcome this condition, so as to improve the safety target value of serum vitamin
D. Osteomalacia in the jaws might be a pivotal factor in MRONJ pathogenesis and should
be considered before starting BPs treatment.
In summary: ONJ is a severe and multifactorial clinical condition; its incidence is low
in cancer, almost irrelevant in osteoporosis. ONJ results from a combination of different
concomitant factors: none of these is singly sufficient to induce ONJ. The main incident
factors beside the presence of an immunosuppressive status, osteomalacia and the use
of antiresorptive agents, are: concomitant assumption of drugs such as steroids, dental
interventions, oral and gingival infections. Moreover, the role played by antiresorptive
drugs has not been completely understood yet, but they do not appear to be the main
culprits in ONJ pathogenesis; the pre-existing condition of general/local osteomalacia
might be a pivotal factor for drugs involvement in the pathogenetic mechanism. Vitamin D
plays an important role in the prevention of ONJ; the safety level of 25-OH vitamin D has
to be investigated (Table 1).
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Table 1. The key points of this review are summarized.
1. ONJ is a severe and multifactorial clinical condition
2. ONJ incidence is low in cancer, almost irrelevant in osteoporosis
3. The incident factors are: immunodeficiency, assumption of drugs such as glucocorticoids, dental interventions, oral andgingival infections
4. A general or local osteomalacia condition may be the main factor in the pathogenetic involvement of antiresorptive drugs
5. Vitamin D is important in the prevention of ONJ
6. The safety levels of 25-OH vitamin D in this pattern need to be specifically investigated
ONJ, osteonecrosis of the jaw.
These considerations point towards some important clinical implications: firstly, BPs
should not be considered direct pathogenetic factors for ONJ; secondly, hypovitaminosis
D correction in immunocompromised patients in view of a dental intervention should
be considered as the antibiotic prophylaxis, before starting a BP treatment. The effective
safety level of serum 25-OH vitamin D in this particular setting should be determined by
ad hoc studies.
Such precautions seem to be more effective for these patients rather than BPs treatment
discontinuation, considering the dramatic impact of fragility fractures.
Further studies are needed to confirm the actual interplay occurring between os-
teomalacia and BPs in ONJ pathogenesis, although the results of the abovementioned
histomorphometric study head towards the acquittal of BPs as the main culprits.
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